Breakthrough Discovery: Shared Genetic Foundations of Multiple Sclerosis
A groundbreaking study from Queen Mary University of London (QMUL) has illuminated the shared genetic underpinnings of multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. Published in the prestigious journal Neurology, the research reveals that key genetic risk factors for MS are consistent across South Asian, African, and European populations, challenging long-held assumptions about the disease's genetic exclusivity to those of European descent.
Led by Dr. Benjamin Jacobs and Professor Ruth Dobson from QMUL's Preventive Neurology Unit, the study analyzed genomic data from over 3,000 MS patients and 27,000 controls, including participants from the UK-based ADAMS (Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis) project. This effort marks a pivotal shift toward inclusive genetic research, particularly relevant for Europe's increasingly diverse populations.
The findings underscore the universal biological pathways driving MS, primarily involving immune dysregulation where the body's T-cells mistakenly attack myelin, the protective sheath around nerve fibers. This leads to symptoms like fatigue, vision loss, mobility issues, and cognitive challenges, profoundly impacting quality of life.
Historical Context: MS Research's Eurocentric Lens
Historically, MS genetic studies have predominantly focused on individuals of European ancestry, with genome-wide association studies (GWAS) identifying over 200 risk loci, largely within the major histocompatibility complex (MHC) region on chromosome 6. This region, crucial for immune response, houses genes like HLA-DRB1 strongly linked to MS susceptibility.
In Europe, MS prevalence is among the world's highest, estimated at 100-300 cases per 100,000 people, peaking in northern countries like Scotland (295/100,000) and Sweden. Yet, underrepresentation of non-European groups has obscured whether these variants generalize globally. For instance, earlier polygenic risk scores (PRS) derived from European data performed poorly in South Asian cohorts, predicting only a fraction of risk.
QMUL's work addresses this gap, reflecting a broader European push for diverse genomics. Institutions like the University of Oxford and University College London have initiated similar inclusive studies, emphasizing ethical data collection from migrant communities prevalent in urban centers like London and Paris.
The ADAMS Project: Pioneering Diverse Genomics at QMUL
The ADAMS project, spearheaded by QMUL since 2022, recruits MS patients from non-European backgrounds in the UK, where South Asian and African diaspora communities number millions. This study leveraged 288 South Asian and 112 African MS cases, genotyped via Illumina arrays and imputed against diverse reference panels like 1000 Genomes.
Researchers employed REGENIE for within-ancestry GWAS, adjusting for principal components to mitigate population stratification. PRS were constructed using PRSice-2 from the International Multiple Sclerosis Genetics Consortium's (IMSGC) European summary statistics, capturing common variants (MAF >5%).
This rigorous methodology mirrors advancements at European hubs like the Wellcome Sanger Institute, fostering collaborations that enhance statistical power through meta-analyses.
Key Findings: Overlapping Risk and Ancestry-Specific Insights
The GWAS pinpointed strong MHC signals in both groups: HLA-DRB1 in South Asians (lead SNP chr6:32600515:G>A, OR=1.84, P=4.6e-6) and HLA-A in Africans (chr6:29919337:A>G, OR=2.24, P=4.3e-5). These align with European peaks, confirming shared immunogenetic drivers.
- 104/154 European risk SNPs directionally concordant in South Asians; 80/152 in Africans.
- European PRS explained 1.6% liability-scale variance in South Asians, 0.5% in Africans—proportional to European SNP-heritability (18-22%).
- Suggestive novel loci: South Asian (ABCA4, ZNF385D); African (HMCN1, LRRTM4).
A protective HLA-DPB1*10:01 allele (OR=0.32) is 3x more frequent in South Asians, potentially explaining lower prevalence (20-50/100,000 vs. 200+/100,000 in Europeans).
Photo by Muhammad Faiz Zulkeflee on Unsplash
Implications for Diagnosis and Risk Prediction
These results validate European PRS for non-Europeans, enabling ancestry-informed screening in multicultural Europe. In the UK, where 14% are Asian and 4% Black, earlier detection could mitigate worse outcomes—Black patients progress to disability 6 years faster.Academic CV tips for neurology researchers.
Professor Dobson notes: “Better representation... leads to better science.” This could refine tools like IMSGC's PRS, used clinically at European centers.
Challenges in MS Across Europe's Diverse Populations
MS affects 800,000+ in Europe, with rising incidence in migrants suggesting environmental triggers like vitamin D deficiency or Epstein-Barr virus. South Asians in UK show similar prevalence to natives but delayed diagnosis; Africans face underreporting.
Stakeholders, including the MS Society, advocate diverse trials. QMUL's work inspires pan-European initiatives, e.g., ECTRIMS network.
Broader Contributions from European Universities
QMUL collaborates with Oxford and Edinburgh on MS cohorts. Recent European studies: Karolinska Institutet's EBV-MS link; Helsinki's PRS for Finns. These converge on immune genetics, paving for universal therapies like ocrelizumab.
Explore research jobs in neurology at European universities.Future Directions: Toward Global MS Genomics
Dr. Jacobs emphasizes: “Diversity matters... to build prediction tools that work for everyone.” Next: larger non-European GWAS, functional studies on novel variants, integration with environmental data.
Europe's genomics infrastructure (UK Biobank, FinnGen) positions it to lead, but funding equity is key. Horizon Europe grants support diverse cohorts.
Photo by Nadzeya Matskevich on Unsplash
Stakeholder Perspectives and Actionable Insights
MS International Federation praises inclusivity. Patients urge biobanks. Researchers seek scholarships for diverse trainees.
- Clinicians: Use ancestry-adjusted PRS for risk assessment.
- Academics: Prioritize recruitment from underrepresented groups.
- Patients: Participate in studies like ADAMS.
Conclusion: Advancing Equitable MS Research in Europe
QMUL's study exemplifies higher education's role in tackling global health via diverse science. As Europe diversifies, such research ensures treatments benefit all. Explore Rate My Professor for neurology experts, higher ed jobs in genomics, or career advice. Stay informed on university innovations driving MS progress.
Read the full Neurology paper | Queen Mary University | University jobs | Postdoc opportunities
